Interventional Radiology Imaging

Which Imaging Is Best for Staging Asymptomatic Acute Myeloid Leukemia in Adults?

·
Which Imaging Is Best for Staging Asymptomatic Acute Myeloid Leukemia in Adults?

A 58-year-old patient is in your clinic, having just received a diagnosis of Acute Myeloid Leukemia (AML) from a bone marrow biopsy. Clinically, they feel well—no fevers, no focal pain, no palpable masses on exam. Before initiating induction chemotherapy, the critical question is whether there is any occult extramedullary disease (EMD). Choosing the right initial staging study is essential for establishing a baseline, identifying sites of disease that might require targeted therapy like radiation, and providing prognostic information. This decision directly impacts the treatment plan. For an asymptomatic adult with a new diagnosis of AML or acute promyelocytic leukemia (APL), the American College of Radiology (ACR) Appropriateness Criteria rate FDG-PET/CT skull base to mid-thigh as Usually Appropriate, providing a comprehensive metabolic and anatomic assessment to guide care.

Who Fits This Clinical Scenario?

This guidance is specifically for an asymptomatic adult patient with a new, pathologically confirmed diagnosis of acute myeloid leukemia (AML) or acute promyelocytic leukemia (APL) requiring initial staging. The key qualifier is “asymptomatic,” meaning the patient has no localizing signs or symptoms—such as focal neurologic deficits, bone pain, or a palpable mass—that would otherwise direct the imaging workup to a specific anatomical area. The primary goal of imaging in this context is to screen for clinically silent extramedullary disease.

This workflow should not be applied to patients who fall into other clinical categories, even if they seem similar. Key exclusions include:

  • Symptomatic Patients: If a patient with AML presents with a headache, imaging would be directed by those symptoms (e.g., a dedicated brain MRI), which follows a different diagnostic algorithm.
  • Different Leukemia Subtypes: This guidance is not intended for initial staging of Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia (CML), or Chronic Lymphocytic Leukemia (CLL). Each of these has distinct patterns of spread and different ACR recommendations.
  • Pediatric Patients: Imaging guidelines and radiation dose considerations differ for children.
  • Follow-up or Post-therapy Evaluation: This article addresses initial staging only. Imaging to assess treatment response or for suspected relapse is a separate clinical question.

What Diagnoses Are You Working Up in This Scenario?

In an asymptomatic adult with newly diagnosed AML or APL, imaging is not for diagnosis but for staging. The primary objective is to identify the full extent of the disease beyond the bone marrow. The differential considerations for imaging findings revolve around manifestations of leukemia and potential co-existing conditions that could complicate therapy.

Extramedullary Disease (Myeloid Sarcoma): This is the most important finding to identify. Myeloid sarcoma (previously called a chloroma or granulocytic sarcoma) is a solid tumor mass composed of leukemic blast cells occurring in a location other than the bone marrow. It can arise in virtually any organ, including skin, lymph nodes, bone, the central nervous system, and viscera. Detecting EMD is prognostically significant and may alter the treatment plan to include localized radiation therapy in addition to systemic chemotherapy.

Occult Infection: Patients with newly diagnosed acute leukemia are profoundly immunocompromised. An imaging study may uncover an unsuspected source of infection, such as a subclinical pneumonia or deep abscess. Identifying and addressing such a finding before initiating intensive immunosuppressive chemotherapy is critical to prevent life-threatening sepsis.

Baseline Anatomic Assessment: A comprehensive baseline scan documents the status of organs and lymph nodes prior to therapy. This is invaluable for future comparisons. If a patient later develops symptoms or a new physical finding, having a pre-treatment scan helps determine if the finding is new, related to the leukemia, or a complication of treatment.

Why Is FDG-PET/CT the Recommended Study for This Presentation?

The ACR designates both FDG-PET/CT skull base to mid-thigh and FDG-PET/CT whole body as Usually Appropriate for the initial staging of an asymptomatic adult with AML/APL. The combined metabolic data from Positron Emission Tomography (PET) and anatomic detail from Computed Tomography (CT) make it the most sensitive modality for detecting clinically occult extramedullary disease.

Myeloid sarcomas are typically hypermetabolic and demonstrate high avidity for fluorodeoxyglucose (FDG), making them conspicuous on PET imaging even when they are not large enough to be considered abnormal by size criteria on a standard CT. This functional information provides a significant advantage over purely anatomic imaging. A whole-body survey can identify widespread disease in a single session, which is more efficient and comprehensive than imaging individual body parts.

In contrast, other imaging modalities are rated lower for this specific screening purpose:

  • CT chest with IV contrast is rated May be appropriate. While it can identify bulky lymphadenopathy or large visceral masses, it lacks the metabolic information of PET and has lower sensitivity for detecting EMD in normal-sized lymph nodes or subtle infiltrative disease.
  • MRI of various body parts is rated Usually not appropriate for a general screening evaluation. While MRI offers superior soft-tissue contrast for a specific, symptomatic area (e.g., the brain or spine), it is impractical and less effective as a primary tool for a whole-body survey for EMD.
  • A whole-body bone scan is also rated Usually not appropriate. It is less sensitive than FDG-PET/CT for detecting leukemic infiltrates in the bone marrow and will not detect EMD in soft tissues.

The primary trade-off with PET/CT is radiation exposure. The typical effective dose is significant (adult relative radiation level ☢☢☢☢, 10-30 mSv), but this risk is generally considered acceptable in the context of staging a life-threatening malignancy where the results directly influence management.

What’s Next After FDG-PET/CT? Downstream Workflow

The results of the staging FDG-PET/CT will guide the subsequent steps in the patient’s management plan. The workflow typically branches based on whether extramedullary disease is detected.

If the study is positive for suspected EMD: A focal, FDG-avid finding consistent with myeloid sarcoma requires careful consideration. If the site is readily accessible (e.g., a superficial lymph node), a biopsy may be performed to confirm the diagnosis, as inflammatory and infectious processes can also be FDG-avid. Confirmation of EMD often leads to a consultation with radiation oncology to consider consolidating therapy with localized radiation, which can improve disease control at that site.

If the study is negative: A negative PET/CT scan provides a valuable baseline and suggests the absence of clinically significant extramedullary disease. The patient can proceed with the planned systemic chemotherapy regimen. This baseline scan remains a crucial reference point if the patient develops new symptoms during or after treatment, helping to differentiate relapse from treatment complications.

If the study is indeterminate: Findings such as low-level or diffuse FDG uptake without a clear anatomic correlate can be challenging. These may represent reactive inflammation, post-biopsy changes, or low-grade leukemic infiltration. In these cases, the next step is close clinical correlation. If a specific site remains suspicious, a targeted, problem-solving study like a dedicated MRI or ultrasound may be warranted. Otherwise, a short-interval follow-up scan after initial therapy may clarify the significance of the finding.

Pitfalls to Avoid (and When to Get Help)

Several common pitfalls can complicate the interpretation and utility of staging PET/CT in this scenario:

  • Misinterpreting Inflammatory Uptake: Many non-malignant processes, including infection and inflammation, are FDG-avid. Always correlate imaging findings with the clinical picture, physical exam, and laboratory data. A recent biopsy site, for example, will be FDG-avid.
  • Incorrect Timing: The PET/CT should be performed before the initiation of any systemic therapy, including high-dose steroids. Treatment can suppress FDG uptake in leukemic cells, potentially leading to a false-negative result and under-staging the disease.
  • Overlooking the CT Component: While the PET data is highly sensitive, the anatomic information from the CT portion is vital. A non-FDG-avid or low-avidity lesion that is anatomically suspicious on CT should not be dismissed.

If the imaging findings are complex, equivocal, or discordant with the clinical presentation, a multidisciplinary discussion involving the hematologist, radiologist, and potentially a radiation oncologist is the best path forward.

Related ACR Topics and Tools

For a comprehensive overview of imaging across all leukemia-related clinical variants, please consult our parent topic guide. For tools to assist in ordering the right scan and understanding the details, see the resources below.

Frequently Asked Questions

Why not just order a diagnostic CT of the chest, abdomen, and pelvis instead of a PET/CT?

A standard contrast-enhanced CT is rated ‘Usually not appropriate’ for this indication. While it provides excellent anatomic detail, it lacks the metabolic information of a PET scan. Myeloid sarcomas can infiltrate organs or lymph nodes without significantly enlarging them, making them invisible on a CT but detectable as FDG-avid spots on a PET/CT. The higher sensitivity of PET/CT for extramedullary disease makes it the preferred staging modality.

Is a PET/CT scan truly necessary if the patient is completely asymptomatic with a normal physical exam?

Yes, it is still considered ‘Usually Appropriate.’ The primary purpose of the scan in this scenario is to detect clinically occult disease. Extramedullary disease can be present and prognostically important even in the absence of symptoms or physical findings. The PET/CT serves as a comprehensive whole-body screen to ensure no sites of disease are missed before starting therapy.

What is the practical difference between a ‘skull base to mid-thigh’ and a ‘whole body’ PET/CT?

Both are rated ‘Usually Appropriate.’ A ‘skull base to mid-thigh’ scan is the most common protocol and covers the areas where extramedullary disease most frequently occurs (head/neck lymph nodes, chest, abdomen, pelvis, and axial skeleton). A ‘whole body’ scan extends coverage to include the lower extremities and the entire brain. The choice may depend on institutional protocol, but for general screening in AML, skull base to mid-thigh is typically sufficient unless there is a specific concern for disease in the distal extremities.

Does this imaging guidance also apply to Acute Lymphoblastic Leukemia (ALL)?

No, this guidance is specific to AML and APL. While PET/CT is also used in ALL, the clinical indications and patterns of disease are different, particularly the higher propensity for central nervous system involvement. The ACR has separate appropriateness criteria for the staging of ALL in both adult and pediatric populations.

What if my patient with new AML has a specific symptom, like a severe headache?

If the patient is symptomatic, the imaging workup changes. A headache would be a red flag for central nervous system (CNS) involvement. In that case, the most appropriate initial study would be a dedicated MRI of the brain with and without IV contrast, not a PET/CT. The principle is to let specific symptoms guide a targeted imaging workup, whereas the PET/CT is reserved for asymptomatic screening.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026